2022
DOI: 10.3892/etm.2022.11755
|View full text |Cite
|
Sign up to set email alerts
|

Meta‑analysis of the efficacy and safety of nifekalant in the conversion of atrial fibrillation

Abstract: Atrial fibrillation (AF) is the most common type of supraventricular tachyarrhythmia. Nifekalant is a new class III antiarrhythmic drug approved for the treatment of ventricular tachyarrhythmias, but its effectiveness in converting AF to sinus rhythm remains unclear. The present analysis aimed to investigate the effect of nifekalant in the conversion of AF. PubMed, Cochrane Library and China National Knowledge Infrastructure databases were systematically used to search relevant studies published between 1999 (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 36 publications
(45 reference statements)
0
1
0
Order By: Relevance
“…It has no significant effect on myocardial cell conduction velocity or myocardial contractility, which translates in a low incidence of adverse events such as bradycardia and hypotension [ 146 ]. When compared with catheter ablation, nifekalant had a better success rate of conversion, with no difference in the incidence of adverse events between the two groups [ 147 ]. Refralon/Niferidil: New class III antiarrhythmic agent developed in Russia for pharmacological cardioversion.…”
Section: Rhythm Control In Atrial Fibrillation: Toward a Translationa...mentioning
confidence: 99%
“…It has no significant effect on myocardial cell conduction velocity or myocardial contractility, which translates in a low incidence of adverse events such as bradycardia and hypotension [ 146 ]. When compared with catheter ablation, nifekalant had a better success rate of conversion, with no difference in the incidence of adverse events between the two groups [ 147 ]. Refralon/Niferidil: New class III antiarrhythmic agent developed in Russia for pharmacological cardioversion.…”
Section: Rhythm Control In Atrial Fibrillation: Toward a Translationa...mentioning
confidence: 99%